Champions Oncology Swings to a Loss as Cash Burn Accelerates and Runway Narrows

summarizeSummary

Champions Oncology reported a fiscal 2026 net loss of $1.2 million, a 43% drop in deferred revenue, and negative operating cash flow of $4.5 million, leaving only $4.9 million in cash and a runway through August 2027.

check_boxKey Events · Earnings and Guidance · CSBR

• Swung to a Net Loss

  Fiscal 2026 net loss of $1.2 million, compared to net income of $4.7 million in fiscal 2025, as operating expenses surged 15.6% while revenue grew only 4%.

• Deferred Revenue Collapsed

  Deferred revenue fell 43% to $8.8 million from $15.4 million, indicating a sharp decline in new bookings and future revenue visibility.

• Cash Burn and Tight Runway

  Cash used in operations was $4.5 million, reducing cash to $4.9 million. Management states cash is adequate only through August 2027, implying a ~12-month runway.

• Negative Working Capital

  Working capital turned negative at -$703,000, reflecting the strain from declining deferred revenue and rising payables.

auto_awesomeAnalysis · CSBR · Life Sciences

Champions Oncology's fiscal 2026 10-K reveals a sharp reversal from the prior year's profitability. The company posted a $1.2 million net loss, driven by a 15.6% jump in operating expenses that outpaced a modest 4% revenue increase. More concerning, deferred revenue—a leading indicator of future work—plummeted 43% to $8.8 million, signaling a significant slowdown in bookings. Cash used in operations was $4.5 million, leaving just $4.9 million in the bank. Management's own liquidity assessment states cash is sufficient only through August 2027, giving the company roughly 12 months of runway. With negative working capital and heavy customer concentration (one client accounts for 24% of revenue), the financial position has materially weakened. The stock is priced at $6.25, but the underlying business is showing clear signs of stress.